Circulating cell-free DNA levels are associated with adverse outcomes in heart failure: testing liquid biopsy in heart failure

Salzano, Andrea; Israr, Muhammad Zubair; Fernández-García, Daniel; Middleton, Laura; D’Assante, Roberta; Marra, Alberto M.; Arcopinto, Michele; Yazaki, Yoshio; Bernieh, Dennis; Cassambai, Shabana; Page, Karen M.; Rengo, Giuseppe; Bossone, Eduardo; Cittadini, Antonio; Shaw, Jacqueline A; Suzuki, Toru

doi:10.1177/2047487320912375

Cited by 18 publications

(11 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While this is the first report demonstrating the utility of total ncfDNA and major cardiac events in heart transplantation, cfDNA has been shown to be predictive of mortality outside of transplantation in studies of adults including those with established cardiovascular disease. 7,13 We suggest that heart transplant recipients with markedly elevated ncfDNA levels warrant increased clinical scrutiny and surveillance.…”

Section: Discussionmentioning

confidence: 97%

Increase in nuclear cell‐free DNA is associated with major adverse events in adult and pediatric heart transplant recipients

Zangwill

Deshpande

Simpson

et al. 2021

Clinical Transplantation

View full text Add to dashboard Cite

Background: Cell-free DNA is an emerging biomarker. While donor fraction may detect graft events in heart transplant recipients, the prognostic value of total nuclear cellfree DNA (ncfDNA) itself is largely unexplored.Objective: Explore the relationship between ncfDNA and clinical events in heart transplant recipients. Methods:We conducted a multi-center prospective study to investigate the value of cell-free DNA in non-invasive monitoring following heart transplantation. Over 4000

show abstract

Section: Discussionmentioning

confidence: 97%

Increase in nuclear cell‐free DNA is associated with major adverse events in adult and pediatric heart transplant recipients

Zangwill

Deshpande

Simpson

et al. 2021

Clinical Transplantation

View full text Add to dashboard Cite

show abstract

“…As shown in Figure 3, cell-free DNA increase has been observed in almost all possible COVID-19 complications. The increase ranges from 2-fold under psychosocial stress conditions [120], 4-fold in chronic kidney disease [121] or lung disease, and up to 5-6-fold in cardiovascular disease (even more in sepsis) [122][123][124].…”

Section: Multiorgan Failurementioning

confidence: 99%

Cell-Free DNA: Potential Application in COVID-19 Diagnostics and Management

Stawski

Nowak

Perdas

2022

Viruses

View full text Add to dashboard Cite

WHO has declared COVID-19 as a worldwide, public health emergency. The elderly, pregnant women, and people with associated co-morbidities, including pulmonary disease, heart failure, diabetes, and cancer are the most predisposed population groups to infection. Cell-free DNA is a very commonly applied marker, which is elevated in various pathological conditions. However, it has a much higher sensitivity than standard biochemical markers. cfDNA appears to be an effective marker of COVID-19 complications, and also serves as a marker of certain underlying health conditions and risk factors of severe illness during COVID-19 infection. We aimed to present the possible mechanisms and sources of cfDNA released during moderate and severe infections. Moreover, we attempt to verify how efficiently cfDNA increase could be applied in COVID-19 risk assessment and how it corresponds with epidemiological data.

show abstract

“…30 The fields of oncology and prenatal screening and diagnostics perpetually exchange developments, and sometimes even intersect when ctDNA is detected during NIPT. 29,31 Also in cardiology and neurogenetics, liquid biopsies have been shown useful for clinical monitoring, for instance for heart failure 32 and neuronal atrophy. 33 Somewhat less known, but not less promising, are the pioneering efforts in cfDNA-based organ transplants monitoring 34,35 and cfDNA-based diagnostics of parasitic 36 , viral 37 or bacterial 38 infections.…”

Section: Figure 1 Timeline Of the Main Events Leading Towards The Development Of Niptmentioning

confidence: 99%

Fragmentomic cfDNA Patterns in Noninvasive Prenatal Testing and Beyond

Kohabir

Wolthuis

Sistermans

2021

J. Biomed. Transl. Res.

View full text Add to dashboard Cite

The release of fetoplacental cell-free DNA (cfDNA) into the maternal bloodstream opened up new avenues towards noninvasive prenatal testing (NIPT) for aneuploidies, hereditary DNA mutations and other pregnancy-related developmental disorders. Increasingly, cfDNA catches interest for its noninvasive screening value in other areas as well, including oncology. Although there are indications that cfDNA fragmentation is a non-random process, the etiology and different structural aspects of cfDNA are still not well known. The emerging field of cfDNA fragmentomics investigates the existence of tissue and disease specific cfDNA signatures and the chemistry and biology underlying the fragmentation process. This review sheds light on recent developments in cfDNA fragmentomics and illustrates their significance in NIPT improvement and beyond.We discuss aspects of fragment size distributions, epigenetic correlations and putatively enriched cfDNA fragment-end compositions. Combinatorial fragmentomic efforts have provided more insights into the roles of different enzymes that contribute to the fragmentation process in the tissue of origin and in the bloodstream. Altogether, these studies revealed multiple fragmentomic-related biomarkers that can be used to make noninvasive screening and other types of clinical use of cfDNA more robust, by raising its distinctive capacities. This includes multiple complementary approaches to determine the fetal fraction, a key determinant in NIPT. Furthermore, these developments translate to a better understanding of the encountered cfDNA patterns and will catalyze the expansion of screening possibilities in NIPT and beyond

show abstract

Circulating cell-free DNA levels are associated with adverse outcomes in heart failure: testing liquid biopsy in heart failure

Cited by 18 publications

References 15 publications

Increase in nuclear cell‐free DNA is associated with major adverse events in adult and pediatric heart transplant recipients

Increase in nuclear cell‐free DNA is associated with major adverse events in adult and pediatric heart transplant recipients

Cell-Free DNA: Potential Application in COVID-19 Diagnostics and Management

Fragmentomic cfDNA Patterns in Noninvasive Prenatal Testing and Beyond

Contact Info

Product

Resources

About